Mr. Moyes has served on our Board since April 2012. Since March 2020, he has served as the Chief Financial Officer of Sera Prognostics, Inc., a private clinical-stage biotechnology company focused on improving maternal and neonatal health through innovative biomarker approaches, Mr. Moyes has been a member of the board of directors of Achieve Life Sciences, Inc., a public specialty pharmaceutical company, since August 2017 and a member of the board of directors and chairman of the audit committee of Osiris Therapeutics, Inc., a publicly held stem cell therapeutics company, since May 2006. He has also been a member of the board of directors and chairman of the audit committee for Biocardia, Inc., a privately held cardiovascular regenerative medicine company, and Integrated Diagnostics, Inc., a privately held molecular diagnostics company, since 2011.
From May 2008 through July 2009, Mr. Moyes served as the Chief Financial Officer of XDx, Inc., a privately held molecular diagnostics company. Prior to that, he served as the Chief Financial Officer of Myriad Genetics, Inc., a publicly held healthcare diagnostics company, from June 1996 until his retirement in November 2007, and as its Vice President of Finance from July 1993 until July 2005. From 1991 to 1993, Mr. Moyes served as Vice President of Finance and Chief Financial Officer of Genmark, Inc., a privately held genetics company. He held various positions with the accounting firm of KPMG LLP from 1979 through 1991, most recently as a Senior Manager. He also served as a member of the Board of trustees of the Utah Life Science Association from 1999 through 2006.
Mr. Moyes holds an MBA from the University of Utah, a B.A. in economics from Weber State University, and is formerly a Certified Public Accountant. He was selected as a director because of his extensive background in finance and accounting in the life sciences industry.
What is Jay M. Moyes' net worth?
The estimated net worth of Jay M. Moyes is at least $30.16 thousand as of February 23rd, 2026. Moyes owns 4,000 shares of Puma Biotechnology stock worth more than $30,160 as of April 28th. This net worth estimate does not reflect any other investments that Moyes may own. Learn More about Jay M. Moyes' net worth.
How do I contact Jay M. Moyes?
Has Jay M. Moyes been buying or selling shares of Puma Biotechnology?
Jay M. Moyes has not been actively trading shares of Puma Biotechnology within the last three months. Most recently, Jay M. Moyes sold 22,000 shares of the business's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $3.40, for a transaction totalling $74,800.00. Following the completion of the sale, the director now directly owns 53,322 shares of the company's stock, valued at $181,294.80. Learn More on Jay M. Moyes' trading history.
Who are Puma Biotechnology's active insiders?
Puma Biotechnology's insider roster includes Alan Auerbach (CEO), Alessandra Cesano (Director), Allison Dorval (Director), Douglas Hunt (Insider), Jeffrey Ludwig (Insider), Ann Miller (Director), Jay Moyes (Director), Maximo Nougues (CFO), Adrian Senderowicz (Director), Brian Stuglik (Director), and Alvin Wong (Insider). Learn More on Puma Biotechnology's active insiders.
Are insiders buying or selling shares of Puma Biotechnology?
During the last year, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 237,586 shares worth more than $951,627.52. The most recent insider tranaction occured on January, 7th when CEO Alan H Auerbach sold 18,012 shares worth more than $105,910.56. Insiders at Puma Biotechnology own 23.3% of the company.
Learn More about insider trades at Puma Biotechnology. Information on this page was last updated on 1/7/2026.
